FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225718797> ?p ?o ?g. }

• W4225718797 endingPage "59" @default.
• W4225718797 startingPage "52" @default.
• W4225718797 abstract "Heparin is the standard anticoagulant for cardiopulmonary bypass (CPB); however, there are problems with its use that make the development of suitable alternatives desirable. Currently, no ideal alternative exists. We have previously reported that the direct thrombin inhibitor dabigatran can prevent coagulation in simulated CPB at high concentrations. These high concentrations may cause difficulties in achieving the reversal of dabigatran with idarucizumab, given the markedly different pharmacokinetics of the 2 drugs. Herein, we test the hypothesis that the addition of the anti-Xa drug rivaroxaban would provide suitable anticoagulation at a lower concentration of dabigatran given likely synergy between the 2 classes of drugs. The primary goal of the study was to investigate whether the addition of rivaroxaban reduces the concentration of dabigatran necessary to allow 2 hours of simulated CPB.The study was performed in sequential steps. Blood collected from consenting healthy donors was used throughout. First, we added graded concentrations of dabigatran and rivaroxaban alone and in combination and assessed inhibition of anticoagulation using thromboelastometry. Using results from this step, combinations of dabigatran and rivaroxaban were tested in both Chandler loop and simulated CPB circuits. Dabigatran and rivaroxaban were added before recalcification, and the circuits were run for 120 minutes. In both models of CPB, 120 minutes of circulation without visible thrombus was considered successful. In the Chandler loop system, idarucizumab was added to reverse anticoagulant effects. In the CPB circuits, the arterial line filters were examined using scanning electron microscope (SEM) to qualitatively assess for fibrin deposition.In vitro analysis of blood samples treated with dabigatran and rivaroxaban showed that dabigatran and rivaroxaban individually prolonged clotting time (CT) in a dose-dependent manner. However, when combined, the drugs behaved synergistically. In the Chandler loop system, dabigatran 2400 and 4800 ng/mL plus rivaroxaban (150 ng/mL) effectively prevented clot formation and reduced the dynamics of clot propagation for 120 minutes. Idarucizumab (250-1000 µg/mL) effectively reversed anticoagulation. In the CPB circuits, dabigatran (2500 ng/mL) and rivaroxaban (200 ng/mL) were successful in allowing 120 minutes of simulated CPB and prevented fibrin deposition. Biomarkers of coagulation activation did not increase during simulated CPB. Heparin controls performed similarly to dabigatran and rivaroxaban.The dual administration of oral anticoagulant drugs (dabigatran and Rivaroxaban) with different pharmacologic mechanisms of action produced synergistic inhibition of coagulation in vitro and successfully prevented clotting during simulated CPB." @default.
• W4225718797 created "2022-05-05" @default.
• W4225718797 creator A5022071420 @default.
• W4225718797 creator A5025144329 @default.
• W4225718797 creator A5026958214 @default.
• W4225718797 creator A5026976261 @default.
• W4225718797 creator A5063956660 @default.
• W4225718797 creator A5089637763 @default.
• W4225718797 creator A5089950134 @default.
• W4225718797 date "2022-04-07" @default.
• W4225718797 modified "2023-10-14" @default.
• W4225718797 title "Rivaroxaban Reduces the Dabigatran Dose Required for Anticoagulation During Simulated Cardiopulmonary Bypass" @default.
• W4225718797 cites W1976542477 @default.
• W4225718797 cites W1996805811 @default.
• W4225718797 cites W2009549527 @default.
• W4225718797 cites W2023022634 @default.
• W4225718797 cites W2026561579 @default.
• W4225718797 cites W2037428681 @default.
• W4225718797 cites W2071283345 @default.
• W4225718797 cites W2140436541 @default.
• W4225718797 cites W2148403944 @default.
• W4225718797 cites W2196626069 @default.
• W4225718797 cites W2767883086 @default.
• W4225718797 cites W2791821230 @default.
• W4225718797 cites W2808475011 @default.
• W4225718797 cites W2883635742 @default.
• W4225718797 cites W3037039196 @default.
• W4225718797 cites W3080531984 @default.
• W4225718797 doi "https://doi.org/10.1213/ane.0000000000006019" @default.
• W4225718797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35389372" @default.
• W4225718797 hasPublicationYear "2022" @default.
• W4225718797 type Work @default.
• W4225718797 citedByCount "5" @default.
• W4225718797 countsByYear W42257187972022 @default.
• W4225718797 countsByYear W42257187972023 @default.
• W4225718797 crossrefType "journal-article" @default.
• W4225718797 hasAuthorship W4225718797A5022071420 @default.
• W4225718797 hasAuthorship W4225718797A5025144329 @default.
• W4225718797 hasAuthorship W4225718797A5026958214 @default.
• W4225718797 hasAuthorship W4225718797A5026976261 @default.
• W4225718797 hasAuthorship W4225718797A5063956660 @default.
• W4225718797 hasAuthorship W4225718797A5089637763 @default.
• W4225718797 hasAuthorship W4225718797A5089950134 @default.
• W4225718797 hasConcept C126322002 @default.
• W4225718797 hasConcept C1621761 @default.
• W4225718797 hasConcept C26809991 @default.
• W4225718797 hasConcept C2776301958 @default.
• W4225718797 hasConcept C2776413415 @default.
• W4225718797 hasConcept C2776710957 @default.
• W4225718797 hasConcept C2777091921 @default.
• W4225718797 hasConcept C2777557582 @default.
• W4225718797 hasConcept C2778205648 @default.
• W4225718797 hasConcept C2778661090 @default.
• W4225718797 hasConcept C2778810321 @default.
• W4225718797 hasConcept C2778881276 @default.
• W4225718797 hasConcept C2779161974 @default.
• W4225718797 hasConcept C42219234 @default.
• W4225718797 hasConcept C71924100 @default.
• W4225718797 hasConcept C98274493 @default.
• W4225718797 hasConceptScore W4225718797C126322002 @default.
• W4225718797 hasConceptScore W4225718797C1621761 @default.
• W4225718797 hasConceptScore W4225718797C26809991 @default.
• W4225718797 hasConceptScore W4225718797C2776301958 @default.
• W4225718797 hasConceptScore W4225718797C2776413415 @default.
• W4225718797 hasConceptScore W4225718797C2776710957 @default.
• W4225718797 hasConceptScore W4225718797C2777091921 @default.
• W4225718797 hasConceptScore W4225718797C2777557582 @default.
• W4225718797 hasConceptScore W4225718797C2778205648 @default.
• W4225718797 hasConceptScore W4225718797C2778661090 @default.
• W4225718797 hasConceptScore W4225718797C2778810321 @default.
• W4225718797 hasConceptScore W4225718797C2778881276 @default.
• W4225718797 hasConceptScore W4225718797C2779161974 @default.
• W4225718797 hasConceptScore W4225718797C42219234 @default.
• W4225718797 hasConceptScore W4225718797C71924100 @default.
• W4225718797 hasConceptScore W4225718797C98274493 @default.
• W4225718797 hasIssue "1" @default.
• W4225718797 hasLocation W42257187971 @default.
• W4225718797 hasLocation W42257187972 @default.
• W4225718797 hasOpenAccess W4225718797 @default.
• W4225718797 hasPrimaryLocation W42257187971 @default.
• W4225718797 hasRelatedWork W2000243320 @default.
• W4225718797 hasRelatedWork W2021321073 @default.
• W4225718797 hasRelatedWork W2042662278 @default.
• W4225718797 hasRelatedWork W2092563904 @default.
• W4225718797 hasRelatedWork W2108742851 @default.
• W4225718797 hasRelatedWork W2146332686 @default.
• W4225718797 hasRelatedWork W2384497685 @default.
• W4225718797 hasRelatedWork W2516475670 @default.
• W4225718797 hasRelatedWork W2911735228 @default.
• W4225718797 hasRelatedWork W4225718797 @default.
• W4225718797 hasVolume "135" @default.
• W4225718797 isParatext "false" @default.
• W4225718797 isRetracted "false" @default.
• W4225718797 workType "article" @default.